Ads
related to: Dupixent Eczema and Sales- FAQs
Find Answers To Your Questions
& Understand Treatment Now
- Getting Started
Learn More About Dosing Schedules
Find Answers To Your Questions
- Home
Official Patient Website—
Get Treatment Info Today.
- Sign Up
Apply Or Activate Your Card—
Find Out If You're Eligible Today.
- Patient Support
Hear From The Ambassadors—
How This Treatment Option Works
- Support Resources
Sign Up And Learn More About The
Patient Education Program Today.
- FAQs
Search results
Sanofi's Dupixent gets U.S. approval to treat eczema in young children
Reuters via Yahoo News· 2 years agoDupixent is now the first approved treatment for moderate-to-severe eczema in young children, Sanofi...
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids
Zacks via Yahoo Finance· 1 year agoSanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat...
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Pharmaceutical Technology via Yahoo Finance· 2 weeks agoRegeneron and Sanofi could soon be adding another indication to its blockbuster immunology drug...
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
Investor's Business Daily· 4 months agoSanofi stock undercut its 50-day line Thursday despite Dupixent outperformance as its earnings...
Sanofi forecasts moderate profit growth on Dupixent demand
Reuters via Yahoo News· 1 year ago(Reuters) -Sanofi forecast moderate earnings growth that undershot expectations, saying demand for...
Regeneron, Sanofi Plot A Major Expansion That Could Add $4 Billion In Future Sales
Investor's Business Daily· 6 months agoRegeneron Pharmaceuticals and Sanofi said Monday their blockbuster drug, Dupixent, significantly...
ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study
Zacks via Yahoo Finance· 3 months agoASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with...
Sanofi Posts Upbeat Q1 Earnings, Sales Buoyed By Blockbuster Dupixent Sales
Benzinga via Yahoo Finance· 1 year agoFrench drugmaker Sanofi SA (NASDAQ: SNY) reported an 8.7% Y/Y (+9.3% on constant currency) rise in...
Sanofi (SNY), Regeneron's Dupixent sBLA Gets FDA Priority Tag
Zacks via Yahoo Finance· 2 weeks agoSanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with...
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
Investor's Business Daily· 1 year agoRegeneron stock surged Friday on stronger-than-expected metrics, though its partner Sanofi posted a...
Ads
related to: Dupixent Eczema and Sales